Whenever a new weight-management medicine appears, the first reasonable question is: does it work, and by how much? For the oral Wegovy pill, the answer comes from a major clinical trial programme called OASIS. This article breaks down what those trials found, how the pill compares with the injection, and the real-world factors that influence how much weight any individual is likely to lose. It is provided for general educational purposes only and is not medical advice.
What is the OASIS trial programme?
OASIS is the series of phase III clinical trials that tested high-dose oral semaglutide (25 mg) for weight management, the formulation now approved as the Wegovy pill. These trials were designed to answer the questions regulators and patients care about: how much weight people lose, how the pill compares with existing treatments, and how well it is tolerated.
This mattered because delivering enough semaglutide through a tablet to match the injection was a genuine pharmaceutical challenge. Semaglutide is a peptide that struggles to survive stomach acid, so the tablet uses a special carrier compound (SNAC) and a strict empty-stomach routine to be absorbed. The OASIS results were the proof that an oral pill could compete with the needle.
The headline number: around 16.6% weight loss
In the OASIS 4 trial, 307 adults with obesity, or overweight with at least one weight-related condition, followed over 64 weeks, those taking once-daily oral semaglutide 25 mg alongside lifestyle support lost an average of about 16.6% of their body weight when they adhered to treatment, compared with roughly 2% on placebo.
Let us translate that into something tangible:
- A person weighing 80 kg losing 16.6% would shed roughly 13 kg.
- A person weighing 100 kg would lose around 16 to 17 kg.
- A person weighing 120 kg would lose close to 20 kg.
These are averages across trial participants, not guarantees, some people lose more and some lose less, but they show the scale of change the medicine can support.
Two numbers you’ll see: 16.6% and 13.6%
You may come across both figures, and it’s worth understanding the difference. The 16.6% reflects weight loss among people who took the medicine as intended throughout the study. The 13.6% is the average across everyone who started the trial, including those who stopped early or didn’t adhere fully. Both are legitimate; they simply answer slightly different questions. The honest takeaway is that consistent use is what unlocks the higher figure.
How does that compare to the injection and placebo?
Two comparisons help put 16.6% in context.
Against placebo, people taking the active medicine lost far more weight than those on a dummy treatment, where weight change was minimal, that gap is what tells researchers the result is down to the medicine.
Against the injection, the pill’s roughly 16.6% average sits broadly alongside the high-dose Wegovy 2.4 mg injection (around 15%). The injectable forms, and especially tirzepatide (Mounjaro), which has shown higher figures, can edge ahead, but the headline for most people is that the pill delivers injection-level results in tablet form, not a diluted version.
Why “when taken consistently” is the key phrase
The strongest results were seen in people who took the medicine consistently, and that’s especially relevant for the pill. The Wegovy pill must be taken on an empty stomach first thing in the morning, with only a small sip of water, and you must wait at least 30 minutes before eating, drinking or taking anything else. Food and liquid in the stomach reduce how much semaglutide is absorbed. Take it with breakfast or skip the waiting period, and you may absorb less of the active dose, which can blunt results. The pill can match the injection, but it asks a little more daily discipline.
What else affects how much you lose?
Medication is a powerful tool, but not the whole story. Several factors influence individual results:
- Diet and nutrition. Semaglutide reduces appetite, but the quality of what you eat still matters. A balanced, protein-adequate diet protects muscle and supports steady fat loss.
- Physical activity. Regular movement, including some resistance exercise, helps preserve lean muscle as you lose weight.
- Reaching the full dose. Both the pill and injection step up gradually; people who tolerate the escalation and reach the 25 mg maintenance dose tend to see the strongest results.
- Consistency over time. Weight loss with GLP-1 medicines builds over months, not days.
- Individual biology. Genetics, starting weight, hormones and other conditions all play a part, which is why results vary.
Keeping the weight off
One of the most important findings across the semaglutide research is that these medicines are intended for long-term weight management, not a short fix. Studies show that when people stop treatment, some weight tends to return over time. That is why the medication is best viewed as part of an ongoing, medically supervised plan, supported by sustainable lifestyle changes and regular review, rather than a short course. Ongoing follow-up consultations are part of responsible care.
The bottom line, and how to access it
The OASIS trials show the Wegovy pill can support average weight loss of around 16.6% of body weight when taken consistently, results that stand alongside the injection. For anyone who has struggled to lose weight through diet and exercise alone, that’s a meaningful change.
To explore whether it’s right for you, complete a short online form, there’s no video or phone call. An Irish-registered doctor reviews your suitability, and if treatment is clinically appropriate, your prescription (a flat €30 fee) can be dispensed through our Northern Ireland pharmacy partners. Not all patients are suitable, and a prescription is not guaranteed; if it isn’t suitable, your fee is refunded.
Frequently asked questions
How much weight can you lose on the Wegovy pill?
In the OASIS 4 trial, adults taking the 25 mg oral dose consistently lost an average of about 16.6% of their body weight over 64 weeks (around 13.6% when measured across all participants, including those who stopped early). In practical terms, that’s roughly 13 kg for someone starting at 80 kg, around 16 to 17 kg at 100 kg, and close to 20 kg at 120 kg. These are trial averages, some people lose more, some less, and results depend heavily on consistency and lifestyle.
Why do I see two different figures 16.6% and 13.6%?
They answer slightly different questions. The 16.6% reflects weight loss among people who took the medicine as intended throughout the study. The 13.6% averages across everyone who started, including those who didn’t complete or fully adhere. Both are valid; the gap simply shows how much consistent use matters.
Does the Wegovy pill work as well as the Wegovy injection?
Yes, broadly. The 25 mg pill’s average of around 16.6% sits alongside the high-dose Wegovy 2.4 mg injection (around 15%). It was developed to be a genuine equivalent, not a weaker option, the main difference is the daily tablet format versus a weekly injection.
How does it compare to Mounjaro (tirzepatide)?
Tirzepatide, the dual-action injection in Mounjaro, has shown higher average weight loss in studies (up to around 22%). So while the Wegovy pill matches the Wegovy injection, some injectable treatments can produce greater average results. The best option for you depends on your individual circumstances and is a decision for your prescriber.
How long does it take to see results on the Wegovy pill?
Weight loss builds gradually rather than overnight. Many people notice reduced appetite within the first few weeks, but meaningful weight loss develops over several months as the dose is stepped up toward the 25 mg maintenance level. The trial results reflect 64 weeks of treatment, so it’s best viewed as a steady, longer-term process.
How much weight might I lose in the first month?
Early weeks are typically about your body adjusting to a low starting dose, so initial weight loss is usually modest. The larger changes come later, once you reach higher doses. Comparing yourself to the headline trial figures too early can be discouraging. Consistency over months is what counts.
Why does reaching the full 25 mg dose matter for results?
The trial results were achieved at the 25 mg maintenance dose. The pill is titrated upward gradually (1.5 mg to 4 mg to 9 mg to 25 mg) to manage side effects, and people who tolerate the escalation and reach the full dose tend to see the strongest results.
Can I improve my results?
Yes. The medicine works best alongside a balanced, protein-adequate diet (which helps protect muscle), regular activity including some resistance exercise, staying consistent with the daily empty-stomach routine so the medicine absorbs properly, and ongoing follow-up. Medication is a powerful tool, but lifestyle still shapes the outcome.
Will I regain the weight if I stop?
Some weight tends to return after stopping, which is well documented across the semaglutide research. That’s why these medicines are used as part of a long-term, medically supervised plan with lifestyle support and follow-up rather than a short course.
Do I have to take the Wegovy pill forever?
Not necessarily, but it’s intended for long-term weight management rather than a quick fix. How long you stay on treatment is a decision made with your prescriber at your follow-up reviews, based on your progress and goals.
How do I get started in Ireland?
Complete a short online form, there’s no video or phone call. An Irish-registered doctor reviews your suitability, with a flat €30 fee for the prescription. If treatment is appropriate, it’s dispensed through our Northern Ireland pharmacy partners, with collection or delivery available. Not all patients are suitable, and a prescription is not guaranteed; if it isn’t suitable, your fee is refunded.
Ready to find out if the Wegovy pill is right for you? Start a consultation today.
This article is for general educational purposes only and does not constitute medical advice. Individual results vary. Prescription-only medicines used in weight management are prescribed solely where an Irish-registered doctor determines it is clinically appropriate following an individual assessment. A prescription is not guaranteed. Always read the patient information leaflet and follow your prescriber’s guidance.
Wegovy® is a registered trademark of Novo Nordisk. This service is not affiliated with, endorsed by, or sponsored by Novo Nordisk.
